BRPI0416187A - método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i - Google Patents

método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i

Info

Publication number
BRPI0416187A
BRPI0416187A BRPI0416187-4A BRPI0416187A BRPI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A
Authority
BR
Brazil
Prior art keywords
fusion
present
class
viruses
initiation region
Prior art date
Application number
BRPI0416187-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert F Garry
Russell B Wilson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BRPI0416187A publication Critical patent/BRPI0416187A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
BRPI0416187-4A 2003-11-04 2004-11-03 método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i BRPI0416187A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51718103P 2003-11-04 2003-11-04
PCT/US2004/036578 WO2005044992A2 (en) 2003-11-04 2004-11-03 Fusion initiation region in rna virus envelope proteins

Publications (1)

Publication Number Publication Date
BRPI0416187A true BRPI0416187A (pt) 2007-01-23

Family

ID=34572923

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416187-4A BRPI0416187A (pt) 2003-11-04 2004-11-03 método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i

Country Status (12)

Country Link
US (5) US7491793B2 (https=)
EP (7) EP2261377B1 (https=)
JP (1) JP5008398B2 (https=)
AT (1) ATE518967T1 (https=)
AU (2) AU2004288218B2 (https=)
BR (1) BRPI0416187A (https=)
CA (1) CA2544848C (https=)
DK (7) DK2261376T3 (https=)
ES (7) ES2372633T3 (https=)
PL (4) PL2261378T3 (https=)
PT (4) PT2261378E (https=)
WO (1) WO2005044992A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372633T3 (es) 2003-11-04 2012-01-25 The Administrators Of The Tulane Educational Fund Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i.
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
PT2170365T (pt) * 2007-06-25 2016-07-12 Autoimmune Tech Llc Composições e métodos inibidores de influenza
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
CN102939101A (zh) 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) * 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US10189878B2 (en) 2014-09-24 2019-01-29 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JP2022551813A (ja) * 2019-09-04 2022-12-14 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 麻疹に対する併用抗ウイルス療法
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
JP7598538B2 (ja) * 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
CN117396492A (zh) * 2021-03-30 2024-01-12 贝勒医学院 用于基于多肽的高效蛋白抑制的方法和组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) * 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) * 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
JPH11209281A (ja) * 1998-01-21 1999-08-03 Daikin Ind Ltd ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
EP1167382A1 (en) * 1999-03-31 2002-01-02 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU7089600A (en) * 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6605427B2 (en) * 2000-02-10 2003-08-12 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
GB0022969D0 (en) 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
JP5180422B2 (ja) * 2000-09-22 2013-04-10 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ浸入のペプチドインヒビター
US7731975B2 (en) * 2001-01-31 2010-06-08 The United States Of America As Represented By The Secretary Of The Army Chimeric filovirus glycoprotein
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
KR100906102B1 (ko) * 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
JP4651213B2 (ja) * 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US20070092936A1 (en) * 2003-05-08 2007-04-26 Haynes Barton F Severe acute respiratory syndrome
EP1633775A2 (en) * 2003-06-13 2006-03-15 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
TW200510450A (en) * 2003-07-21 2005-03-16 Nat Inst Health Soluble fragments of the SARS-CoV spike glycoprotein
ES2372633T3 (es) 2003-11-04 2012-01-25 The Administrators Of The Tulane Educational Fund Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i.

Also Published As

Publication number Publication date
EP2261374A3 (en) 2011-03-02
PT2261376E (pt) 2013-09-23
EP2261375A3 (en) 2011-06-22
EP2261376A3 (en) 2011-02-23
ATE518967T1 (de) 2011-08-15
US9056900B2 (en) 2015-06-16
DK2261374T3 (da) 2012-09-10
EP2261375B1 (en) 2013-01-23
EP1692265A2 (en) 2006-08-23
ES2400456T3 (es) 2013-04-10
US20060280754A1 (en) 2006-12-14
AU2004288218B2 (en) 2009-12-24
US8598116B2 (en) 2013-12-03
WO2005044992A2 (en) 2005-05-19
PT2261377E (pt) 2013-11-29
DK2261377T3 (da) 2014-01-06
EP2261378A3 (en) 2011-06-15
ES2437858T3 (es) 2014-01-14
EP2261376B1 (en) 2013-07-10
PL1692265T3 (pl) 2011-12-30
ES2372633T3 (es) 2012-01-25
ES2427847T3 (es) 2013-11-04
EP2261377B1 (en) 2013-10-02
DK1692265T3 (da) 2011-11-21
EP2261376A2 (en) 2010-12-15
EP2261374B1 (en) 2012-06-06
AU2010201046A1 (en) 2010-04-08
EP2261378A2 (en) 2010-12-15
WO2005044992A3 (en) 2006-12-07
EP2261374A2 (en) 2010-12-15
PL2261376T3 (pl) 2014-04-30
PL2261377T3 (pl) 2014-03-31
ES2435941T3 (es) 2013-12-26
DK2261375T3 (da) 2013-04-22
US20150239940A1 (en) 2015-08-27
HK1152081A1 (en) 2012-02-17
US7491793B2 (en) 2009-02-17
EP2261377A3 (en) 2011-05-18
JP5008398B2 (ja) 2012-08-22
DK2261380T3 (da) 2013-10-07
DK2261378T3 (da) 2014-01-20
DK2261376T3 (da) 2013-10-07
EP2261375A2 (en) 2010-12-15
EP1692265A4 (en) 2007-08-29
EP1692265B1 (en) 2011-08-03
PT2261378E (pt) 2013-12-09
HK1152085A1 (en) 2012-02-17
US20120289458A1 (en) 2012-11-15
EP2261377A2 (en) 2010-12-15
EP2261380A2 (en) 2010-12-15
EP2261378B1 (en) 2013-10-09
HK1152084A1 (en) 2012-02-17
HK1152086A1 (en) 2012-02-17
PL2261378T3 (pl) 2014-03-31
ES2392891T3 (es) 2012-12-14
HK1152083A1 (en) 2012-02-17
AU2010201046B2 (en) 2013-06-27
US9725487B2 (en) 2017-08-08
US20090264362A1 (en) 2009-10-22
EP2261380B1 (en) 2013-07-17
JP2007514408A (ja) 2007-06-07
EP2261380A3 (en) 2011-02-23
PT1692265E (pt) 2011-10-11
CA2544848C (en) 2015-12-29
AU2004288218A1 (en) 2005-05-19
ES2425600T3 (es) 2013-10-16
US20140045743A1 (en) 2014-02-13
CA2544848A1 (en) 2005-05-19
HK1152082A1 (en) 2012-02-17

Similar Documents

Publication Publication Date Title
BRPI0416187A (pt) método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
Albarino et al. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
EP1507791A4 (en) ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
NZ598000A (en) Composition for treating hbv infection
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EP1623012A4 (en) ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
NO20052058L (no) Behandling av influensa.
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
WO2005063281A3 (de) Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
Scheidler et al. Inactivation of viruses by β-propiolactone in human cyro poor plasma and IgG concentrates
WO2010014248A3 (en) Antiviral activity of the protein scytovirin and methods of use
BRPI0418093A (pt) vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral
PH12022553394A1 (en) Conjugate of double-stranded sirna analogue
DE602005027479D1 (de) Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
Mega et al. Mutagenic analysis of Hazara nairovirus nontranslated regions during single-and multistep growth identifies both attenuating and functionally critical sequences for virus replication
Ellenberg et al. Synthesis and expression of viral antigens in Vero cells persistently infected with Junin virus
Madsen Dependence of Two Arboviruses on the Host MicroRNA Pathway
TW200519210A (en) Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same
DE50309164D1 (de) Verwendung von amphiphilen nucleosid-phosphonoameisensäure-derivaten zur behandlung von viralen infektionskrankheiten
TW200738626A (en) Methods for treating hepatitis C

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020120000076/RJ DE 02/01/2012, E NECESSARIO COMPLEMENTAR A GUIA RELATIVA A CESSAO, BEM COMO RECOLHER A GUIA REFERENTE A ESTA EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: AUTOIMMUNE TECHNOLOGIES, LLC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

B25G Requested change of headquarter approved

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL